| Date Filed | Type | Description |
| 03/27/2019 |
GN
| Recent Analysis Shows Transocean, Chipotle Mexican Grill, Marathon Oil, Laboratory Corporation of America, Bio-Rad Laboratories, and Graco Market Influences — Renewed Outlook, Key Drivers of Growth |
| 03/23/2018 |
GN
| Detailed Research: Economic Perspectives on CTS, Lindblad Expeditions, AmeriGas Partners, BBX Capital, Bio-Rad Laboratories, and Inter Parfums — What Drives Growth in Today's Competitive Landscape |
| 06/28/2017 |
GN
| Adamas Appoints New Chief Financial Officer |
| 06/27/2011 |
BW
| BioAlliance Pharma Submits a Phase III Clinical Trial Application for Livatag® (doxorubicin Transdrug™) to the French Drug Agency (Afssaps) |
| 06/24/2011 |
BW
| BioAlliance Pharma Submits Application for Orphan Medicinal Product Designation for Clonidine Lauriad™ in Europe and the United States |
| 05/30/2011 |
BW
| A new Chief Executive Officer to strengthen BioAlliance Pharma's growth |
| 05/25/2011 |
BW
| BioAlliance Pharma: Combined Ordinary and Extraordinary General Meeting on June 29th 2011 |
| 05/20/2011 |
BW
| Board Evolution at BioAlliance Pharma to Support Its Growth Strategy |
| 05/16/2011 |
BW
| BioAlliance Pharma announces that Therabel launches Loramyc® in Germany with the support of Hikma |
| 05/13/2011 |
BW
| Q1 2011: achievement of key milestones in BioAlliance Pharma's clinical development program |
| 05/11/2011 |
BW
| BioAlliance Pharma expands its Loramyc® franchise in Japan with Sosei in a deal valued up to 18.5M$ |
| 04/27/2011 |
BW
| BioAlliance Pharma Accelerates Its European Clinical Development of Clonidine Lauriad™ |
| 04/13/2011 |
MW
| Bio-Rad to Report First-Quarter 2011 Financial Results Tuesday, May 3, 2011 |
| 03/31/2011 |
BW
| BioAlliance Pharma: Livatag® (Doxorubicin Transdrug™) Follow up Demonstrates Significant Survival Increase in Advanced Hepatocellular Carcinoma Patients |
| 03/03/2011 |
BW
| BioAlliance Pharma Receives €2 Million in Funding for Peptide Applications of the Patented LauriadTM Mucoadhesive Technology |
| 03/03/2011 |
BW
| BioAlliance Pharma: Full-Year Financial Results for 2010 |
| 02/24/2011 |
MW
| Bio-Rad Reports Record Fourth-Quarter and Full-Year 2010 Financial Results |
| 02/10/2011 |
BW
| BioAlliance Pharma: Consolidated Turnover for 2010 Exceptional Performance Linked to International Licensing Agreements |
| 01/26/2011 |
MW
| Bio-Rad to Report Fourth-Quarter and Full-Year 2010 Financial Results Thursday, February 24, 2011 |
| 12/15/2010 |
BW
| Bioalliance Pharma Announces New Opportunities for Its Patented Lauriad™ Mucoadhesive Technology |
| 12/06/2010 |
MW
| Bio-Rad Announces Pricing of Public Offering of $425 Million Senior Notes |
| 12/06/2010 |
MW
| Bio-Rad Announces Public Offering of $425 Million Senior Notes |
| 11/23/2010 |
BW
| BioAlliance Pharma Presents Preclinical and Phase I Clinical Results with Its AMEP® Biotherapy for Metastatic Melanoma |
| 11/02/2010 |
MW
| Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of More Than 5 Percent |
| 10/21/2010 |
BW
| The Structure of BioAlliance Pharma's Turnover for Q3 2010 Reflects the Dynamism of the Company's American and European Collaborations |
| 10/19/2010 |
BW
| Dismissal of the civil action filed by Eurofins against BioAlliance in the United States confirmed by the US court of appeals |
| 10/13/2010 |
MW
| Bio-Rad and Axis-Shield Announce FDA Clearance and U.S. Launch of an Anti-CCP Test for Rheumatoid Arthritis for Bio-Rad's BioPlex 2200 System |
| 10/12/2010 |
MW
| Bio-Rad to Report Third-Quarter 2010 Financial Results Tuesday, November 2, 2010 |
| 08/26/2010 |
BW
| BioAlliance Pharma: Acyclovir Lauriad®: US registration file submission planned end-2011 |
| 08/25/2010 |
BW
| BioAlliance Pharma SA: Consolidated Accounts for the First Semester of 2010 |
| 08/24/2010 |
BW
| BioAlliance Pharma Announces the Launch of Oravig® on the US Market by Its Commercial Partner, Strativa/Par Pharmaceutical |
| 08/04/2010 |
BW
| Changes on BioAlliance Pharma General Management |